The infusion from the two pharmaceutical giants brings PathAI’s total Series B funding to $75 million; the startup initially raised $60 million in the round in April. Since its 2016 founding, the Boston-based PathAI has now raised more than $90 million.
The funding will support PathAI’s growing capabilities in clinical development. As David Rubin, PhD, managing director of the Merck innovation fund, explained in a news release, “[PathAI’s] industry-leading work incorporating artificial intelligence into digital pathology holds the potential to change the way we diagnose and treat cancer.”
More articles on AI:
Geisinger, Mayo Clinic, IBM among 25 participants chosen for CMS AI challenge
Patients don’t trust AI — here’s how providers can change that
How Facebook, NYU School of Medicine are using AI to speed MRI readings
